246 related articles for article (PubMed ID: 29512034)
1. Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies.
Trentin F; Gatto M; Zen M; Larosa M; Maddalena L; Nalotto L; Saccon F; Zanatta E; Iaccarino L; Doria A
Clin Rev Allergy Immunol; 2018 Apr; 54(2):331-343. PubMed ID: 29512034
[TBL] [Abstract][Full Text] [Related]
2. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
[TBL] [Abstract][Full Text] [Related]
3. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study.
Iaccarino L; Andreoli L; Bocci EB; Bortoluzzi A; Ceccarelli F; Conti F; De Angelis R; De Marchi G; De Vita S; Di Matteo A; Emmi G; Emmi L; Gatto M; Gerli R; Gerosa M; Govoni M; Larosa M; Meroni PL; Mosca M; Pazzola G; Reggia R; Saccon F; Salvarani C; Tani C; Zen M; Frigo AC; Tincani A; Doria A
J Autoimmun; 2018 Jan; 86():1-8. PubMed ID: 28935492
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland.
von Kempis J; Duetsch S; Reuschling N; Villiger R; Villiger PM; Vallelian F; Schaer DJ; Mueller RB
Swiss Med Wkly; 2019 Feb; 149():w20022. PubMed ID: 30852830
[TBL] [Abstract][Full Text] [Related]
5. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.
Hui-Yuen JS; Reddy A; Taylor J; Li X; Eichenfield AH; Bermudez LM; Starr AJ; Imundo LF; Buyon J; Furie RA; Kamen DL; Manzi S; Petri M; Ramsey-Goldman R; van Vollenhoven RF; Wallace DJ; Askanase A
J Rheumatol; 2015 Dec; 42(12):2288-95. PubMed ID: 26523030
[TBL] [Abstract][Full Text] [Related]
7. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.
Touma Z; Sayani A; Pineau CA; Fortin I; Matsos M; Ecker GA; Chow A; Iczkovitz S
Rheumatol Int; 2017 Jun; 37(6):865-873. PubMed ID: 28280970
[TBL] [Abstract][Full Text] [Related]
8. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
Schwarting A; Dooley MA; Roth DA; Edwards L; Thompson A; Wilson B
Lupus; 2016 Dec; 25(14):1587-1596. PubMed ID: 27488472
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.
Wallace DJ; Ginzler EM; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Petri M; Fettiplace J; Roth DA; Ji B; Heath A
Arthritis Rheumatol; 2019 Jul; 71(7):1125-1134. PubMed ID: 30771238
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
Jordan NP; D'Cruz DP
Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
[TBL] [Abstract][Full Text] [Related]
11. Belimumab: targeted therapy for lupus.
Chugh PK; Kalra BS
Int J Rheum Dis; 2013 Feb; 16(1):4-13. PubMed ID: 23441766
[TBL] [Abstract][Full Text] [Related]
12. Belimumab: review of use in systemic lupus erythematosus.
Boyce EG; Fusco BE
Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.
Abrahamowicz M; Esdaile JM; Ramsey-Goldman R; Simon LS; Strand V; Lipsky PE
Arthritis Rheumatol; 2018 Sep; 70(9):1450-1458. PubMed ID: 29648686
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.
Kalunian KC; Urowitz MB; Isenberg D; Merrill JT; Petri M; Furie RA; Morgan-Cox MA; Taha R; Watts S; Silk M; Linnik MD
Rheumatology (Oxford); 2018 Jan; 57(1):125-133. PubMed ID: 29045736
[TBL] [Abstract][Full Text] [Related]
15. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
[TBL] [Abstract][Full Text] [Related]
16. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
[TBL] [Abstract][Full Text] [Related]
17. Belimumab in the treatment of Portuguese Systemic Lupus Erythematosus patients: a real-life multicenter study.
Fernandes BM; Barreira S; Fonseca JE; Cunha M; Santos MJ; Gonçalves N; Fernandes AL; Rodrigues J; Fontes T; Costa L; Bernardes M
Acta Reumatol Port; 2020; 45(3):170-176. PubMed ID: 33139681
[TBL] [Abstract][Full Text] [Related]
18. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
Iaccarino L; Bettio S; Reggia R; Zen M; Frassi M; Andreoli L; Gatto M; Piantoni S; Nalotto L; Franceschini F; Larosa M; Fredi M; Punzi L; Tincani A; Doria A
Arthritis Care Res (Hoboken); 2017 Jan; 69(1):115-123. PubMed ID: 27390293
[TBL] [Abstract][Full Text] [Related]
19. Update on belimumab for the management of systemic lupus erythematosus.
Lutalo PM; D'Cruz DP
Expert Opin Biol Ther; 2014 Nov; 14(11):1701-8. PubMed ID: 25303323
[TBL] [Abstract][Full Text] [Related]
20. Belimumab for the treatment of systemic lupus erythematosus.
Jordan N; D'Cruz DP
Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
